TY - JOUR
T1 - Susceptibility of Mexican Brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis
AU - López-Merino, Ahidé
AU - Contreras-Rodríguez, Araceli
AU - Migranas-Ortiz, Roberto
AU - Orrantia-Gradín, Rubén
AU - Hernández-Oliva, Gerardo M.
AU - Gutiérrez-Rubio, Arturo Torres Y.
AU - Cardeñosa, Oscar
PY - 2004/10/11
Y1 - 2004/10/11
N2 - Brucellosis is a disease of domestic and wild animals that is transmitted to humans and exists worldwide. We assessed the in vitro activity of moxifloxacin, ciprofloxacin, tetracycline, doxicycline, rifampin, streptomycin and trimethoprim-sulfamethoxazole (TMP/SMX) against 97 Brucella strains isolated from clinical samples, animals and dairy products in Mexico. Fluoroquinolones showed an antibacterial activity similar to that of tetracyclines (MIC900.5). Other drugs commonly used against brucellosis were less active, such as rifampin (MIC902.0 μ/ml) and streptomycin (MIC904.0 μ/ml). TMP/SMX showed the poorest activity (MIC908.0 μg/ml). Fluoroquinolones, either first-generation or the newer 8-methoxi derivatives, might be useful in the therapy of brucellosis, which remains to be assessed in clinical trials. © 2004 Taylor & Francis.
AB - Brucellosis is a disease of domestic and wild animals that is transmitted to humans and exists worldwide. We assessed the in vitro activity of moxifloxacin, ciprofloxacin, tetracycline, doxicycline, rifampin, streptomycin and trimethoprim-sulfamethoxazole (TMP/SMX) against 97 Brucella strains isolated from clinical samples, animals and dairy products in Mexico. Fluoroquinolones showed an antibacterial activity similar to that of tetracyclines (MIC900.5). Other drugs commonly used against brucellosis were less active, such as rifampin (MIC902.0 μ/ml) and streptomycin (MIC904.0 μ/ml). TMP/SMX showed the poorest activity (MIC908.0 μg/ml). Fluoroquinolones, either first-generation or the newer 8-methoxi derivatives, might be useful in the therapy of brucellosis, which remains to be assessed in clinical trials. © 2004 Taylor & Francis.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=4644345011&origin=inward
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=4644345011&origin=inward
U2 - 10.1080/00365540410020767
DO - 10.1080/00365540410020767
M3 - Article
SN - 0036-5548
SP - 636
EP - 638
JO - Scandinavian Journal of Infectious Diseases
JF - Scandinavian Journal of Infectious Diseases
ER -